Drug Profile
Manelimab - Biocad
Alternative Names: Anti PD-L1 monoclonal antibody - Biocad; BCD-135Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Biocad
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Solid-tumours(First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Russia
- 06 Mar 2018 Preclinical trials in Cancer in Russia (unspecified route) (Biocad pipeline, March 2018)
- 31 Oct 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, First-line therapy, Second-line therapy or greater) in Russia (unspecified route) (NCT03464032)